Skip to content
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
Three years after the passage of the Inflation Reduction Act (IRA), patient advocates and the biotech industry are working to navigate downstream negative impacts […]
PACE: Downstream effects of IRA on patients Read More »
Luke Rosen had hoped a new treatment would slow the progression of his daughter’s KIF1A Associated Neurological Disorder (KAND), but was amazed to see
PACE panel urges incentives for exciting new GTT drugs Read More »
The 340B program, in recent decades, has shown how the best laid plans can go sideways when not kept transparent and properly in check.
PACE: How 340B outgrew its goal and stopped helping patients Read More »
The FDA is hiring reviewers and finding ways to expedite drug approval, Dr. George Tidmarsh, Director of the Food and Drug Administration (FDA) Center
PACE: CDER director discusses faster approval, FDA morale with BIO CEO John F. Crowley Read More »
With Medicaid cuts expected, vaccine hesitancy getting politicized, and the continued challenge of Prescription Drug Affordability Boards (PDABs), state legislatures will drive many of
BIO PACE 2025: Patients need to ensure state policies enable access to medicine Read More »
The post-COVID era has not been kind to legislation supportive of vaccines, on either the state or the federal level. But advocates have persisted
BIO PACE 2025: Why patient advocates are key to the vaccine conversation Read More »
The rapidly growing biotech ecosystem supporting innovation in Texas received national attention during a visit by the Biotechnology Innovation Organization (BIO) on Sept. 15-16.
BIO on the American Road: Everything’s big in Texas, including biotech Read More »
At this year’s BIO International Convention in Boston, Riboway Therapeutics emerged as the winner of the 2025 BIO Start-Up Stadium seed-stage category. For founder and
Riboway Therapeutics: Resilience, RNA, and redefining the undruggable Read More »
A Rat sarcoma (RAS) mutation is an oncogene, a gene that causes cancer when mutated. The RAS is the most commonly mutated oncogene in
Startup Stadium: Tezcat Biosciences targets common cancer mutation Read More »
“Initial weight loss is just the first chapter,” said Mia de Graaf, Deputy Executive Health Editor at Business Insider, “but the real challenge and
BIO 2025: How weight loss drugs are disrupting chronic disease Read More »
